Skip to main content
SpringerLink
Log in

Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease

  • Original Papers
  • Published:
European Journal of Drug Metabolism and Pharmacokinetics Aims and scope Submit manuscript

Summary

The measurement of plasma drug concentrations provides no insight into the relationship between the free and the plasma-protein-bound fractions of drugs. Plasma protein binding may decrease in renal disease due to uremia, hypoalbuminemia, or due to drug interactions. Decreased plasma protein binding leads to an increase in free plasma fraction causing an increase in volume of distribution and a shorter elimination half life. The increase in the apparent volume of distribution and the shorter elimination half life cause a decrease in total plasma concentration. Therefore, the free drug concentration is more reliable than the total plasma concentration for therapeutic drug monitoring. However, the free amount in plasma and in tissue and the tissue-bound amount remain unchanged under steady state conditions. Thus, a decrease in plasma protein binding in renal disease usually does not lead to increased drug toxicity, and alteration of drug dosage is not required, although the total plasma concentration may be found to be considerably lower than normal. In addition to plasma protein binding, alteration of tissue binding must also be considered for the determination of the appropriate dosage of some drugs in renal disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Adler D.S. (1979): Phenytoin. Clin. Toxicol.,14, 147–150.

    Article  CAS  Google Scholar 

  2. Antilla M., Haataja M. and Kasanen A. (1980): Pharmacokinetics of Naproxen in subjects with normal and impaired renal function. Europ. J. Clin. Pharmacol.,18, 263–268.

    Article  Google Scholar 

  3. Aronson J.K. (1983): Clinical pharmacokinetics of cardiac glycosides in patients with renal dysfunction. Clin. Pharmacokin.,8, 155–178.

    Article  CAS  Google Scholar 

  4. Bachmann K., Shapiro R. (1977): Protein binding of coumarin anticoagulants in disease states. Clin. Pharmacokinet.,2, 110–126.

    Article  CAS  PubMed  Google Scholar 

  5. Bachmann K., Sullivan T.J. (1982): Effect of plasma protein binding on clearance of drugs metabolized by Michaelis-Menten kinetics. J. Pharm. Sei.,71, 374–375.

    Article  CAS  Google Scholar 

  6. Belpaire F.M., Bogaert M.G. and Mussche M.M. (1977): Influence of acute renal failure on the protein binding of drugs in animal and in man. Europ. J. Clin. Pharmacol.,11, 27–32.

    Article  CAS  Google Scholar 

  7. Bennett W.M., Muther R.S., Parker R.A., Feig P., Morrison G., Golper T.A. and Singer I. (1980): Drug therapy in renal failure : dosing guidelines for adults. Ann. Int. Med.,93, 286–325.

    CAS  PubMed  Google Scholar 

  8. Bergrem H. (1983): Pharmacokinetics and protein binding of prednisolone in patients with nephrotic syndrome and patients undergoing hemodialysis. Kidney Int.,23, 876–888.

    Article  CAS  PubMed  Google Scholar 

  9. Blouin R.A., Erwin W.G., Dutro M.P., Bustrack J.A. and Rowse K.L. (1980): Chloramphenicol hemodialysis clearance. Therap. Drug Monitor,2, 351–354.

    CAS  Google Scholar 

  10. Bowmer C.J. and Lindup W.E. (1982): Decreased drug binding in uremia: effect of indoxyl sulfate and other endogenous substances on the binding of drugs and dyes ot human albumine. Biochem. Pharmacol.,31, 319–323.

    Article  CAS  PubMed  Google Scholar 

  11. Clegg L.S. and Lindup W.E. (1982): Drug binding defect of uremic plasma : unlikely involvement of carbamoylated albumin. Biochem. Pharmacol.,31, 2791–2794.

    Article  CAS  PubMed  Google Scholar 

  12. D’Arcy P.F. and McElnay J.C. (1982): Drug interactions involving the displacement of drugs from plasma protein and tissue binding sites. Pharmbc. Therap.,17, 211–220.

    Article  Google Scholar 

  13. Frey F.J., Gambertoglio J.G., Frey B.M., Benet L.Z. and Amend W.J.C. (1982): Nonlinear plasma protein binding and haemodialysis clearance of prednisolone. Europ. J. Clin. Pharmacol.,23, 65–74.

    Article  CAS  Google Scholar 

  14. Frey F.J. and Frey B.M. (1982): Altered prednisolone kinetics in patients with the nephrotic syndrome. Nephron.,32, 45–48.

    Article  CAS  PubMed  Google Scholar 

  15. Garcia M.J., Dominguez-Gil A., Tabernero J.M. and Sanchez Tomero J. A. (1979): Pharmacokinetics of cefoxitin in patients with normal or impaired renal function. Europ. J. clin. Pharmacol.,16, 119–124.

    Article  CAS  Google Scholar 

  16. Giacomini K.M., Gibson T.P. and Levy G. (1978): Plasma protein binding of d-Propoxyphene in normal subjects and anephric patients. J. Clin. Pharm.,18, 106–109.

    CAS  Google Scholar 

  17. Giacomini K.M., Swezey S.E., Turner-Tamiyasu K. and Blaschke T.F. (1982): The effect of saturable binding to plasma proteins on the pharmacokinetic properties of disopyramide. J. Pharmacokinet Biopharm.,10, 1–14.

    Article  CAS  PubMed  Google Scholar 

  18. Greenblatt D.J., Sellers E.M. and Koch-Weser J. (1982): Importance of protein binding for the interpretation of serum or plasma drug concentrations. J. Clin. Pharmacol.,22, 259–263.

    CAS  PubMed  Google Scholar 

  19. Greenblatt D.J., Murray T.G., Audet P.R., Locniskar A., Koepke H.H. and Walker B.R. (1983): Multiple-dose kinetics and dialyzability of Oxazepam in renal insufficiency. Nephron.,34, 234–238.

    Article  CAS  PubMed  Google Scholar 

  20. Greene D.S. and Tice A.D. (1977): Effect of hemodialysis on Cefazolin protein binding. J. Pharm. Sei.,66, 1508–1510.

    Article  CAS  Google Scholar 

  21. Gugler R., Shoeman D.W., Huffmann D.H., Cohlmia J.B. and Azarnoff D.L. (1975): Pharmacokinetics of drugs in patients with the nephrotic syndrome. J. Clin. Invest.,55, 1182–1189.

    Article  CAS  PubMed  Google Scholar 

  22. Holford N.H.G. and Sheiner L.B. (1981): Understanding the dose-effect relationship: clinical application of Pharmacokinetic-pharmacodynamic models. Clin. Pharmacokin.,6, 429–453.

    Article  CAS  Google Scholar 

  23. Holley F.O., Fonganis K.V. and Stanski D.R. (1982): Effect of cardiopulmonary bypass on the pharmacokinetics of drugs. Clin. Pharmacokinet.,7, 234–251.

    Article  CAS  PubMed  Google Scholar 

  24. Houin G., Brunner F., Nebout T., Cherfoui M., Lagrue G. and Tillement J.P. (1983): The effect of chronic renal insufficiency on the pharmacokinetics of doxycycline in man. Br. J. Clin. Pharm.,16, 245–252.

    CAS  Google Scholar 

  25. Hulter H.N., Licht J.H., Illnick L.P. and Singh S. (1979): Clinical efficacy and pharmacokinetics of Clonidine in hemodialysis and renal insufficiency. J. Lab. Clin. Med.,94, 223–231.

    CAS  PubMed  Google Scholar 

  26. Iliopoulou A., Downey K., Chaput de Saintonge D.M. and Turner P. (1982): Should erythromycin dose be altered in haemodialysis patients? Europ. J. Clin. Pharmacol.,23, 435–440.

    Article  CAS  Google Scholar 

  27. Keller F., Hauff A., Schultze G., Offermann G., Reeck S., Molzahn M., Kreutz G. and Vöhringer H. F. (1984): Effect of repeated plasma exchange on steady state kinetics of digoxin and digitoxin. Arzneim. Forsch.,34, 83–86.

    CAS  Google Scholar 

  28. Kessler K.M. and Perez G.O. (1981): Decreased quinidine plasma protein binding during hemodialysis. Clin. Pharmacol. Therap.,30, 121–126.

    CAS  Google Scholar 

  29. Kinniburgh D.W. and Boyd N.D. (1981): Phenytoin binding to partially purified albumin in renal disease. Clin. Pharmacol. Therap.,29, 203–210.

    CAS  Google Scholar 

  30. Kragh-Hansen U. (1981): Molecular aspects of ligand binding to serum albumin. Pharmacol. Reviews,33, 17–53.

    CAS  Google Scholar 

  31. Kramer P., Koethe E., Saul J. and Scheler F. (1974): Uremic and normal plasma protein binding of various cardiac glycosides under ‘in vivo’ conditions. Europ. J. Clin. Invest.,4, 53–58.

    Article  CAS  PubMed  Google Scholar 

  32. Levy G. and Yacobi A. (1974): Effect of plasma protein binding on elimination of Warfarin. J. Pharm. Sei.,63, 805–806.

    Article  CAS  Google Scholar 

  33. Levy G. (1976): Effect of plasma protein binding of drugs on duration and intensity of pharmacological activity. J. Pharm. Sei.,65, 1264–1265.

    Article  CAS  Google Scholar 

  34. Levy R.H. and Moreland T.A. (1984): Rationale for monitoring free drug levels. Clin. Pharmacokin.,9 (SI), 1–9.

    Article  CAS  Google Scholar 

  35. Lichtenwalder D.M., Suh B., Lorber B. and Rudnick M.R. (1982): Correction of drug binding defects in uremia in vitro by anion exchange resin treatment. Biochem. Pharmacol.,31, 3483–3487.

    Article  Google Scholar 

  36. Lichtenwalder D.M., Suh B. and Lichtenwalner M.R. (1983):Isolation and chemical characterization of 2-hydroxybenzolglycine as a drug binding inhibitor in uremia. J. Clin. Invest.,71, 1289–1296.

    Article  Google Scholar 

  37. Lima J.J. (1983): Experimental evidence for concentration-dependent plasma protein binding effects on the apparent half-lives of restrictively cleared drugs. J. Pharm. Sei.,72, 461–462.

    Article  CAS  Google Scholar 

  38. Martin E., Gambertoglio J.G., Adler D.S., Tozer T.N., Roman L.A. and Gransz H. (1977): Removal of phenytoin by hemodialysis in uremic patients. J. Am. Med. Assoc.,238, 1750–1753.

    Article  CAS  Google Scholar 

  39. McNamara P.J., Gibaldi M. and Stoeckel K. (1983): Volume of distribution terms for a drug (Ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations. Europ. J. Clin. Pharmacol.,25, 399–405.

    Article  CAS  Google Scholar 

  40. Naranjo CA., Khouw V. and Sellers E.M. (1982): Nonfatty acid-modulated variations in drug binding due to Heparin. Clin. Pharmacol. Therap.,31, 746–752.

    CAS  Google Scholar 

  41. Odar-Cederlöf J., Borga O. (1974): Kinetics of Diphenyl-hydantoin inuraemic patients: consequences of decreased plasma protein binding. Europ. J. Clin. Pharmacol.,7, 31–37.

    Article  Google Scholar 

  42. Odar-Cederlöf I. (1977): Plasma protein binding of Phenytoin and Warfarin in patients undrgoing renal transplantation. Clin. Pharmacokinet.,2, 147–153.

    Article  PubMed  Google Scholar 

  43. O’Malley K., Velasco M., Pruitt S. and McNay J.L. (1975): Decreased plasma protein binding of diazoxide in uremia. Clin. Pharmacol. Therap.,18, 53–58.

    Google Scholar 

  44. Pearson R.M. and Breckenridge A.M. (1976): Renal function, protein binding and pharmacological response to diazoxide. Br. J. Clin. Pharm.,3, 169–175.

    CAS  Google Scholar 

  45. Piafsky K.M. (1980): Disease-induced changes in the plasma binding of basic drugs. Clin. Pharmacokinet.,5, 246–262.

    Article  CAS  PubMed  Google Scholar 

  46. Rane A., Villeneuve J. P., Stone W.J., Nies A.S., Wilkinson G.R. and Branch R.A. (1978): Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia. Clin. Pharmacol. Therap.,24, 199–207.

    CAS  Google Scholar 

  47. Reidenberg M.M., Odar-Cederlöf J., Von Bah C, Borga O. and Sjöqvist F. (1971): Protein binding of Diphenylhydantoin and Desmethylimipramine in plasma form patients with poor renal function. N. Engl. J. Med.,285, 264–267.

    Article  CAS  PubMed  Google Scholar 

  48. Reidenberg M.M. and Drayer D.E. (1984): Alteration of drug-protein binding in renal disease. Clin. Pharmacokin.,9, (SI), 18–26.

    Article  Google Scholar 

  49. Richens A. (1979): Clinical pharmacokinetics of phenytoin. Clin. Pharmacokin.,4, 153–169.

    Article  CAS  Google Scholar 

  50. Rimmer E.M., Buss D.C., Routledge P.A. and Richens A. (1984): Should we routinely measure free plasma phenytoin concentration? Br. J. Clin. Pharm.,17, 99–102.

    CAS  Google Scholar 

  51. Robertz G.M. and Dengler H.J. (1983): Endogenous ligand(s) decrease drug-protein binding in uremic sera: a fluorescence probe study. Klin. Wochenschr.,61, 649–653.

    Article  CAS  PubMed  Google Scholar 

  52. Rowland M. (1972): Influence of route of administration on drug availability. J. Pharm. Sei.,61, 70–74.

    Article  CAS  Google Scholar 

  53. Schneider R.E., Bishop H. (1982): β-blocker plasma concentration and inflammatory disease : clinical implications. Clin. Pharmacokinet.,7, 281–284.

    Article  CAS  PubMed  Google Scholar 

  54. Singhvi S.M., Heald A.F. and Schreiber E.C. (1978): Pharmacokinetics of cephalosporin antibiotics: protein-binding considerations. Chemotherapy,24, 121–133.

    Article  CAS  PubMed  Google Scholar 

  55. Steele W.H., Lawrence J.R., Elliott H.L. and Whiting B. (1979): Alteration of phenytoin protein binding with in vivo haemodialysis in dialysis encephalopathy. Europ. J. Clin. Pharmacol.,15, 69–71.

    Article  CAS  Google Scholar 

  56. Storstein L. (1977): Protein binding of cardiac glycosides in disease states. Clin. Pharmacokinet.,2, 220–233.

    Article  CAS  PubMed  Google Scholar 

  57. Tozer T.N. (1981): Concepts basic to pharmacokinetics. Pharmacol. Therap.,12, 109–131.

    Article  CAS  Google Scholar 

  58. Verbeeck R.K. and De Schepper P.J. (1980): Influence of chronic renal failure and hemodialysis on diflunisal plasma protein binding. Clin. Pharmacol. Therap.,27, 628–635.

    CAS  Google Scholar 

  59. Wilkinson G.R. and Shand D.G. (1975): A physiological approach to hepatic drug clearance. Clin. Pharmacol. Therap.,18, 377–390.

    CAS  Google Scholar 

  60. Yeung J.H.K., Breckenridge A.M. and Park B.K. (1983): Drug-protein conjugates — IV. The effect of acute renal failure on the disposition of (14C)Captopril in the rat. Biochem. Pharmacol.,32, 2467–2472.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsklinikum Steglitz, Freie Universität Berlin, Hindeburgdamm 30, D-1000, Berlin, 45

    F. Keller, M. Maiga, H. -H. Neumayer, H. Lode & A. Distler

Authors
  1. F. Keller
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Maiga
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. -H. Neumayer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. Lode
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Distler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keller, F., Maiga, M., Neumayer, H.H. et al. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. European Journal of Drug Metabolism and Pharmacokinetics 9, 275–282 (1984). https://doi.org/10.1007/BF03189651

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03189651

Keywords

Search

Navigation